Please assess the completion status of the following clinical trial:

Trial Title: BKM120+Abiraterone Acetate for Metastatic CRPC

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed CRPC with metastatic bone disease~* Castrate resistant disease~* Life expectancy of at least 6 months~* At least four weeks from previous treatment~* At least four weeks since any major surgery or radiation therapy~* Using highly effective contraception~Exclusion Criteria:~* Thromboembolism within past 6 months~* History of diabetes~* Prior therapy with abiraterone~* Prior therapy with PI3K inhibitor~* Alcohol or drug dependence currently or within past 6 months~* Contraindications to biopsy, such as bleeding disorders~* On anticoagulants such as warfarin or heparin~* Active malignancy other than skin cancer or superficial bladder cancer~* Untreated brain metastases~* Acute or chronic liver, renal disease or pancreatitis~* Mood disorders judged by the investigator to interfere with study participation~* Active cardiac disease or history of cardiac dysfunction~* Uncontrolled hypertension~* Known HIV, Hepatitis B or C~* Serious non-healing wound, ulcer or bone fracture~* Known or suspected allergy to BKM120, abiraterone or prednisone~* Impairment of GI function

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment Arm (Type: EXPERIMENTAL): BKM120+Abiraterone+Prednisone

Based on this trial design, predict the completion outcome and termination type (if applicable).